Projects in multiple myeloma
PANACEA: Prognostic impact of Proton Pump Inhibitors on response to CAR T-cells
Efficacy and safety of CAR-T in T cell/histiocyte-rich large B-cell lymphoma patients
Infectious complications following CAR T-Cells injection
CARTAGE : CAR T-cells in patients aged 75 years and older with diffuse large B cell lymphoma
Study of macrophage activation syndrome associated CAR T-cells in patients with lymphoma and ALL
HGBL – Tolerance and Efficacy of CAR-T in high-grade B-cell lymphoma
BMS – Profile of patients in Intent-to-Treat with CAR T-cells, and Efficacy and Safety in relapsed or refractory Large B-Cell Lymphomas
TRANSCAR : Comparison of the efficacy and safety of CAR-T in “de novo” DLBCL VS transformed indolent lymphoma (tNHL)
DLBCL – First results of CAR T-cell therapy in patients diagnosed with large B cell lymphoma
DLBCL L2 – 1rst results of axi-cel in 2nd-line of treatement for Large B-Cell Lymphoma
LF – First results of axi-cel and tisa-cel in patients with follicular lymphoma
ETCETERA: Efficacy and safety of CAR-T cells in non-Hodgkin lymphomas with central nervous system involvement
T-cell malignancies after CAR T-cell therapy
DLBCL – Impact of Bridging therapies in Patients with Diffuse Large B-cell Lymphoma After 3 or More Lines of Treatment
Sociology and public health thesis: The cell, the industry and the hospital; the healthcare system and the CAR-T promise
Efficacy and safety of CAR-T cells in immunocompromised patients
TARMAC: Efficacy and safety of CAR-T cells in mantle cell lymphomas with central nervous system involvement
DLBCL-3L- Analysis of the DLBCL cohort after 3 or more lines of treatment: outcome of patients according to their response
LAL – Persistence of B aplasia following CAR T-cells in cute lymphocytic leukemia: impact on the incidence and nature of relapses
Relapses post CAR-T-cell treatment in mantle cell lymphoma
PLWH – People Living With HIV treated by CAR-T in R/R aggressive B-cell lymphomas
CAREFUL: Prognostic impact of intesive care admission for organ suppleance following CAR T-cells
Abbvie – Profile of patients in Intent-to-Treat with CAR T-cells, and Efficacy and Safety in Large B-Cell Lymphomas
Comparative control arm of Phase II clinical trial BICAR with the DESCAR-T registry
Efficacy and safety of CAR-T in the treatment of primary mediastinal lymphoma
Analysis of fungal infections after CAR-T
Use of Siltuximab in the treatment of Cytokine Release Syndromes
Miltenyi – CAR-T efficacy and safety in diffuse large B-cell lymphoma
CARLATE: Outcome of patients relapsing more than 3 months after CAR T-Cell therapy
Treating Richter Syndrome with CAR-T